SEARCH

SEARCH BY CITATION

References

  • 1
    Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 2003; 88: 94108.
  • 2
    Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 21746.
  • 3
    Van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, Van Genderen PJ, Fijnheer R. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 17985.
  • 4
    Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 334451.
  • 5
    Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 16915.
  • 6
    Lenting PJ, Van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 135360.
  • 7
    Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontata E, Bertomoro A, Dandone V, Pagnan A, Casonato A. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 35405.
  • 8
    Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 3340.
  • 9
    Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 2004; 103: 9417.
  • 10
    Lenting PJ, Westein E, Terraube V, Ribba A-S, Huizinga EJ, Meyer D, De Groot PG, Denis CV. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279: 121029.
  • 11
    Stoddart JH Jr, Andersen J, Lynch DC. Clearance of normal and type 2 A von Willebrand factor in the rat. Blood 1996; 88: 16929.
  • 12
    Van Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Van Mourik JA, Hollestelle MJ, Vos HL, Bertina RM, Van den Berg HM, Eikenboom JCJ, Lenting PJ, Denis CV. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005; 3: 222837.
  • 13
    Van Schooten CJ, Shahbazi S, Groot E, Oortwijn BD, Van Den Berg HM, Denis CV, Lenting PJ. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008; 112: 170412.
  • 14
    Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111: 35319.
  • 15
    De La Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand’s disease to treatment with desmopressin. Ann Intern Med 1985; 103: 614.
  • 16
    Casonato A, Pontara E, Sartorello F, Cattini Mg, Sartori MT, Padrini R, Girolami A. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002; 99: 1804.
  • 17
    Castaman G, Missiaglia E, Federici AB, Schneppenheim R, Rodeghiero F. An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation. Thromb Hemost 2000; 84: 3501.
  • 18
    Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111: 497985.
  • 19
    Millar CM, Riddell AF, Brown SA, Starke R, Mackie I, Bowen DJ, Jenkins PV, Van Mourik JA. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost 2008; 99: 91624.
  • 20
    Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 6: 76271.
  • 21
    Castaman G, Tosetto A, Federici AB, Rodeghiero F. A prospective evaluation of bleeding tendency and efficacy of antihemorrhagic treatments in patients with increased von Willebrand factor (VWF) clearance (von Willebrand disease Vicenza and C1130F mutation. Blood 2008; 112; Abstract 3385.